



Changes to Medicare Part D Benefits May Help Reduce Out-of-Pocket (OOP) Costs for Medicare Part D Patients Prescribed CRESEMBA¹

Astellas Pharma US, Inc. makes no guarantee regarding reimbursement for any service or item. The information provided in this document is intended for informational purposes only and is not a comprehensive description of potential OOP costs for patients.

The information provided here should not be considered a guarantee of coverage or reimbursement for CRESEMBA.




Starting in 2025, Medicare Part D Patients Will Pay No More Than \$2000 OOP per Year for Their Eligible Part D Drugs^{1*}

- Starting in 2025, the Medicare Part D OOP spending cap will be \$2000.¹ This OOP cap applies to all drugs covered under Medicare Part D for the entire year of 2025¹
- The spending cap only applies to Medicare Part D. Claims billed through Medicare Part B do not apply towards the Medicare Part D OOP spending cap¹
- Beginning in 2025, the Medicare Prescription Payment Plan will allow Medicare Part D patients to opt into paying OOP pharmacy costs over the course of their plan year instead of upfront payments at the point of sale.^{1,2} Patients can enroll in this monthly payment plan option during the annual enrollment period, which began **October 15, 2024, or at any point during the patient’s coverage**^{2†}
- In 2025, the full-subsidy Extra Help will continue to be extended to anyone who traditionally qualified for partial subsidy Extra Help.¹ To qualify for Extra Help, patients must be enrolled in a Medicare prescription drug plan, live in one of the 50 states or District of Columbia, and have income no higher than 150% of the Federal Poverty Level along with limited assets^{1,3}


In 2025, the patient **OOP spending cap will be \$2000 per year** for all Medicare Part D patients¹

Billing for CRESEMBA (isavuconazonium sulfate) May Vary Between Patients With Medicare as They Transition Between Sites of Care and Dosage Forms of CRESEMBA^{4,5}

**When CRESEMBA is administered by an HCP in the hospital[‡]**

- Typically CRESEMBA 372 mg for **injection**⁶

Typically billed through **Medicare Part B**⁴

**When CRESEMBA is self-administered by the patient in an outpatient setting[‡]**


- CRESEMBA 186 mg **capsules**⁶
- CRESEMBA 74.5 mg **capsules**⁶

Billed through **Medicare Part D**⁵

Patient OOP costs for **oral and IV formulations** may vary based on **where the patient receives CRESEMBA and which dosage form is administered**^{1,4,5}

HCP, healthcare provider; IV, intravenous.
^{*}Amount to be indexed to rise each year after 2025 at the rate of growth per capita Part D costs. This cap does not apply to OOP spending on Part B drugs.¹
[†]Whether this option will benefit a particular beneficiary will depend on individual circumstances and preferences. Patients should reach out to their Part D plans to ensure that they understand their coverage and OOP costs before enrolling in this option.
[‡]Does not account for all types of billing or administration modalities.

CRESEMBA Support SolutionsSM Can Help With Prescription Claim Processing for Patients with Medicare Part D



Insurers are required to consider formulary exception requests by federal law.⁷ Further instruction and support can be found through the patient’s plan or at [cms.gov](https://www.cms.gov)


PA, prior authorization.

Formulary Exception Requests Are Granted When a Plan Sponsor Determines That a Requested Drug Is Medically Necessary for an Enrollee⁷

For a formulary exception request to be granted, CRESEMBA must be the appropriate choice based on the physician's clinical expertise.⁷ A formulary exception request must contain all pertinent information as to why formulary medications cannot be utilized.⁷

Resources Are Available to Help Providers Write a Supporting Statement

Further instructions and support can be found through the patient's plan, [cms.gov](https://www.cms.gov), or CRESEMBA Support SolutionsSM

 **CRESEMBA[®]**
(isavuconazonium sulfate)
372 mg for injection
74.5 mg • 186 mg capsules

 **SUPPORTSM**
SOLUTIONS

References: **1.** Kaiser Family Foundation. Changes to Medicare Part D in 2024 and 2025 under the Inflation Reduction Act and how enrollees will benefit. Published April 20, 2023. Accessed July 12, 2024. <https://www.kff.org/medicare/issue-brief/changes-to-medicare-part-d-in-2024-and-2025-under-the-inflation-reduction-act-and-how-enrollees-will-benefit/>. **2.** Centers for Medicare & Medicaid Services. Medicare Prescription Payment Plan: draft part two guidance on select topics, implementation of section 1860D-2 of the Social Security Act for 2025, and solicitation of comments. Published February 15, 2024. Accessed July 15, 2024. <https://www.cms.gov/files/document/medicare-prescription-payment-plan-draft-part-two-guidance.pdf>. **3.** Social Security. Extra Help with Medicare Prescription Drug plan costs. Accessed July 24, 2024. <https://secure.ssa.gov/i1020/start>. **4.** U.S. Department of Health and Human Services. What is Medicare Part B? Published August 7, 2024. Accessed October 24, 2024. <https://www.hhs.gov/answers/medicare-and-medicaid/what-is-medicare-part-b/index.html>. **5.** Kaiser Family Foundation. A current snapshot of the Medicare Part D prescription drug benefit. Published October 9, 2024. Accessed October 24, 2024. <https://www.kff.org/medicare/issue-brief/a-current-snapshot-of-the-medicare-part-d-prescription-drug-benefit/>. **6.** CRESEMBA. Package insert. Northbrook, IL: Astellas Pharma US, Inc; 2023. **7.** Centers for Medicare & Medicaid Services. Exceptions. Updated September 10, 2024. Accessed October 17, 2024. <https://www.cms.gov/medicare/appeals-grievances/prescription-drug/exceptions>.



© 2024 Astellas Pharma Inc. or its affiliates. Printed in USA.
All trademarks are the property of their respective owners.
MAT-US-CRE-2024-00132 11/24

 **CRESEMBA[®]**
(isavuconazonium sulfate)
372 mg for injection
74.5 mg • 186 mg capsules